Assay development and inhibition of the Mt-DprE2 essential reductase from Mycobacterium tuberculosis
Microbiology · 2023
DOI: 10.1099/mic.0.001288 ↗Kurz gefasst
Fachartikel in der Zeitschrift Microbiology, 2023. Verfasst von Sarah M Batt und 10 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Microbiology and Infection, School of Biosciences, University of Birmingham, Birmingham B15 2TT, UK. Hauptthemen laut MEDLINE: Mycobacterium tuberculosis. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical Research Council, Medical Research Foundation.
Abstract (Originalsprache)
DprE2 is an essential enzyme in the synthesis of decaprenylphosphoryl-β- d -arabinofuranose (DPA) and subsequently arabinogalactan, and is a significant new drug target for M. tuberculosis . Two compounds from the GSK-177 box set, GSK301A and GSK032A, were identified through Mt -DprE2-target overexpression studies. The Mt -DprE1-DprE2 complex was co-purified and a new in vitro DprE2 assay developed, based on the oxidation of the reduced nicotinamide adenine dinucleotide cofactor of DprE2 (NADH/NADPH). The Mt -DprE1-DprE2 complex showed interesting kinetics in both the DprE1 resazurin-based assay, where Mt -DprE2 was found to enhance Mt -DprE1 activity and reduce substrate inhibition; and also in the DprE2 assay, which similarly exhibited substrate inhibition and a difference in kinetics of the two potential cofactors, NADH and NADPH. Although, no inhibition was observed in the DprE2 assay by the two GSK set compounds, spontaneous mutant generation indicated a possible explanation in the form of a pro-drug activation pathway, involving fgd1 and fbiC .
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Microbiology and Infection, School of Biosciences, University of Birmingham, Birmingham B15 2TT, UK.
- Diseases of the Developing World, GlaxoSmithKline, Severo Ochoa 2, 28760, Tres Cantos, Madrid, Spain.
- School of Chemistry, University of Birmingham, Edgbaston, Birmingham, UK.
Förderung
- Medical Research Council
- Medical Research Foundation
Zitieren
APA
Batt, S. M., Toth, S., Rodriguez, B., Abrahams, K. A., Veerapen, N., Chiodarelli, G., Cox, L. R., Moynihan, P. J., Lelievre, J., Fütterer, K., & Besra, G. S. (2023). Assay development and inhibition of the Mt-DprE2 essential reductase from Mycobacterium tuberculosis. Microbiology. https://doi.org/10.1099/mic.0.001288
Vancouver
Batt SM, Toth S, Rodriguez B, Abrahams KA, Veerapen N, Chiodarelli G, et al. Assay development and inhibition of the Mt-DprE2 essential reductase from Mycobacterium tuberculosis. Microbiology. 2023. doi:10.1099/mic.0.001288
BibTeX
@article{Batt2023,
author = {Batt, Sarah M and Toth, Szilvi and Rodriguez, Beatriz and Abrahams, Katherine A and Veerapen, Natacha and Chiodarelli, Giacomo and Cox, Liam R and Moynihan, Patrick J and Lelievre, Joel and Fütterer, Klaus and Besra, Gurdyal S},
title = {Assay development and inhibition of the Mt-DprE2 essential reductase from Mycobacterium tuberculosis},
journal = {Microbiology},
year = {2023},
doi = {10.1099/mic.0.001288}
}
EUVIMED